

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	BRAF	<p>Studies in mice identified BRAF inhibitors that could be optimized to help treat cancer. In mice, oral dosing of an aminoisoquinoline BRAF inhibitor prevented tumor xenograft growth. Next steps include studying the biology of BRAF inhibition, including whether compensatory activation of mitogen-activated protein kinase occurs.</p> <p>At least four companies have BRAF inhibitors in clinical and preclinical testing to treat cancers.</p> <p>SciBX 2(38); doi:10.1038/scibx.2009.1433 Published online Oct. 1, 2009</p>	Patent application filed covering the inhibitor; licensing status unavailable	<p>Smith, A. <i>et al. J. Med. Chem.</i>; published online Sept. 18, 2009; doi:10.1021/jm901081g</p> <p>Contact: Adrian L. Smith, Amgen Inc., Thousand Oaks, Calif. e-mail: adrians@amgen.com</p>